Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention

Hanis Zulkifly, Gregory Y. H. Lip, Deirdre A. Lane, Kefang WANG

Research output: Contribution to journalJournal articleResearchpeer-review

23 Downloads (Pure)

Abstract

Introduction. Efficacy and safety of vitamin K antagonists (VKAs) among atrial fibrillation (AF) patients are enhanced when the International Normalised Ratio (INR) is 2.0–3.0. Anticoagulation control among older patients is perceived to be lower and contributes to poorer initiation and uptake. Objective. To examine the quality of INR control, adverse clinical outcomes, and factors associated with bleeding in older AF patients (≥80 years). Methods. Anticoagulation control assessed by time in therapeutic range (TTR) (Rosendaal method) and percentage INRs in range (PINRR). Among the 205 patients aged ≥80 years, 58.5% were female, with mean (SD) CHA2DS2-VASc 4.4 (1.3) and HAS-BLED 1.8 (0.8) scores. Results. Mean (SD) TTR and PINRR were similar for those aged ≥80 vs.
Original languageEnglish
Article number5951262
JournalInternational Journal of Clinical Practice
Volume2022
Pages (from-to)5951262
Number of pages8
ISSN1368-5031
DOIs
Publication statusPublished - 2022

Bibliographical note

Copyright © 2022 Hanis Zulkifly et al.

Keywords

  • Aged
  • Aged, 80 and over
  • Anticoagulants/adverse effects
  • Atrial Fibrillation/complications
  • Female
  • Fibrinolytic Agents/therapeutic use
  • Hemorrhage/chemically induced
  • Humans
  • International Normalized Ratio/adverse effects
  • Male
  • Stroke/complications
  • Vitamin K

Fingerprint

Dive into the research topics of 'Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention'. Together they form a unique fingerprint.

Cite this